Adrian M. Di Bisceglie, MD, FACP; Michael W. Fried, MD; Alessio Michele Aghemo, MD, PhD; and Darius Moradpour, MD
Two major developments—the recommendation for birth cohort screening and the recent approval of all-oral treatment regimens—are poised to change the landscape of HCV patient care. This special conference brings together a distinguished faculty from around the world to discuss the pathogenesis,
diagnosis, and treatment of the disease.
At this event, you will learn about new therapeutic options that can cure the vast majority of patients. You will also leave the conference with insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy.
This live activity is designed for hepatologists, gastroenterologists, NPs/PAs, epidemiologists, pharmacists and others with an interest in hepatitis C epidemiology and therapy.